Quick Answer
Cue Biopharma, Inc. reported Operating Income of -$26.55 million for fiscal year 2025.
Cue Biopharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$26.55M | +36.0% |
| 2024 | -$41.50M | +20.4% |
| 2023 | -$52.15M | +2.0% |
| 2022 | -$53.23M | -21.8% |
| 2021 | -$43.71M | +3.0% |
| 2020 | -$45.04M | -22.5% |
| 2019 | -$36.77M | +5.0% |
| 2018 | -$38.70M | -66.6% |
| 2017 | -$23.23M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.59M | +13.8% | +12.0% |
| June 30, 2025 | -$8.63M | +16.8% | +29.8% |
| March 31, 2025 | -$12.30M | +2.9% | -39.5% |
| September 30, 2024 | -$8.81M | +22.8% | +15.1% |
| June 30, 2024 | -$10.38M | +23.2% | +18.0% |
| March 31, 2024 | -$12.67M | +5.3% | -10.9% |
| September 30, 2023 | -$11.42M | -3.5% | +15.5% |
| June 30, 2023 | -$13.52M | -3.3% | -1.0% |
- Cue Biopharma, Inc. showed an increase of +36.0% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, Cue Biopharma, Inc.’s operating income has declined by 14.3% (from -$23.23 million to -$26.55 million).
- The most recent figure is from Cue Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: